Alokesh Duttaroy

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index3.7kcitations45works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(25), Neuropeptides and Animal Physiology(24), Neuroscience and Neuropharmacology Research(12), Pain Mechanisms and Treatments(11), Pancreatic function and diabetes(8)

Publications45 total

GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice
Diabetologia·2017· 45 citedOpen Access
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV
Bioorganic & Medicinal Chemistry Letters·2014· 19 citedOpen Access
Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960
European Journal of Pharmacology·2013· 3 cited
Erratum to “Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes” [Bioorg. Med. Chem. Lett. 22 (2012) 1464–1468]
Bioorganic & Medicinal Chemistry Letters·2012· 10 cited
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Bioorganic & Medicinal Chemistry Letters·2011· 68 citedOpen Access
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes II: Optimisation of the PK profile
2011
CRYSTAL STRUCTURE OF HUMAN DPP4 IN COMPLEX WITH A NOVAL HETEROCYCLIC DPP4 INHIBITOR
2011· 1 cited
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
European Journal of Pharmacology·2010· 64 cited
Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes
Journal of Medicinal Chemistry·2009· 91 cited
The Insulin Receptor Talks to Glucagon?
Cell Metabolism·2009· 17 citedOpen Access
Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
Diabetes·2008· 33 citedOpen Access
Role of the M <sub>3</sub> muscarinic acetylcholine receptor in β‐cell function and glucose homeostasis
Diabetes Obesity and Metabolism·2007· 73 cited
M&lt;sub&gt;1&lt;/sub&gt;-M&lt;sub&gt;3&lt;/sub&gt; Muscarinic Acetylcholine Receptor-Deficient Mice: Novel Phenotypes
Journal of Molecular Neuroscience·2006· 27 cited
Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology
Diabetes·2005· 128 citedOpen Access
Generation and analysis of muscarinic acetylcholine receptor knockout mice
2004
Muscarinic Stimulation of Pancreatic Insulin and Glucagon Release Is Abolished in M3 Muscarinic Acetylcholine Receptor–Deficient Mice
Diabetes·2004· 198 citedOpen Access
Muscarinic Acetylcholine Receptor Knockout Mice
Handbook of experimental pharmacology·2004· 73 cited
Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology
Life Sciences·2003· 76 cited
Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice
Life Sciences·2003· 99 cited
An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis
Nature Biotechnology·2003· 193 cited
page 1 of 3Next →

Frequent Co-authors

Byron C. Yoburn(17), Jürgen Wess(14), Masahisa Yamada(10), Chu‐Xia Deng(9), Christian C. Felder(8), Sukrut Shah(8), Yinghong Cui(7), Jesús Gomeza(6), Tsuyoshi Miyakawa(5), Garry Fenton(5), Richard Sedrani(5), Kenji Namoto(5), Nils Ostermann(5), Finton Sirockin(5), Ulrich Hassiepen(5), Daniel K. Baeschlin(5), Joanne Carroll(5), Weilie Zhang(4), Frank P. Bymaster(4), Anthony S. Basile(4)